← back to search

Melissa G. Lechner

University of California, Los Angeles · US
Area of research
Oncology · Endocrinology, Diabetes and Metabolism
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses, Thyroid Cancer Diagnosis and Treatment, and Thyroid Disorders and Treatments.
h-index
27
citations
3,843
works
148
NIH funding
primary concept
email

Recent publications

Medullary Thyroid Carcinoma and Clinical Outcomes in Heterozygous Carriers of the <i>RET</i> K666N Germline Pathogenic Variant
JCEM Case Reports 2025cited by 1position: lastdoi
NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024
Journal of the National Comprehensive Cancer Network 2024cited by 96position: middledoi
A pathologically expanded, clonal lineage of IL-21–producing CD4+ T cells drives inflammatory neuropathy
Journal of Clinical Investigation 2024cited by 14position: middledoi
Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium
Journal of Clinical Oncology 2023cited by 65position: middledoi
Clonally expanded, thyrotoxic effector CD8 <sup>+</sup> T cells driven by IL-21 contribute to checkpoint inhibitor thyroiditis
Science Translational Medicine 2023cited by 37position: firstdoi
Prognostic Value of Preoperative Molecular Testing and Implications for Initial Surgical Management in Thyroid Nodules Harboring Suspected (Bethesda V) or Known (Bethesda VI) Papillary Thyroid Cancer
JAMA Otolaryngology–Head & Neck Surgery 2023cited by 37position: middledoi
Spectrum of Clinical Presentations, Imaging Findings, and HLA Types in Immune Checkpoint Inhibitor–Induced Hypophysitis
Journal of the Endocrine Society 2023cited by 27position: middledoi
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network 2022cited by 412position: middledoi
Inhibition of IL-17A Protects against Thyroid Immune-Related Adverse Events while Preserving Checkpoint Inhibitor Antitumor Efficacy
The Journal of Immunology 2022cited by 45position: firstdoi
Pathogenic TNF-α drives peripheral nerve inflammation in an Aire-deficient model of autoimmunity
Proceedings of the National Academy of Sciences 2022cited by 38position: middledoi
Anaplastic Large Cell Lymphoma Occurring in Women with Breast Implants
Plastic & Reconstructive Surgery 2014cited by 338position: middledoi
Immunogenicity of Murine Solid Tumor Models as a Defining Feature of In Vivo Behavior and Response to Immunotherapy
Journal of Immunotherapy 2013cited by 365position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Maureen A. Su · QB35 papers (2022–2024)Willy Hugo · APLA Health4 papers (2022–2024)Trevor E. Angell · University of Southern California3 papers (2013–2023)Ho-Chung Chen · University of California, Los Angeles3 papers (2022–2024)Anushi Y. Patel · Orange County Research Center3 papers (2022–2023)Aline T. Hoang · University of California, Los Angeles3 papers (2022–2023)Ethan C. McCarthy · University of California, Los Angeles3 papers (2022–2024)Antoni Ribas · UCLA Medical Center2 papers (2022–2023) · 2 papers (2022–2022)Michael W. Yeh · University of California, Los Angeles2 papers (2023–2025)Alexandra Drakaki · University of Colorado Denver2 papers (2022–2023)Mandy I. Cheng · University of California, Los Angeles2 papers (2022–2022)Alan L. Epstein · University of Southern California2 papers (2013–2014)Lauren N Scott · University of Kansas1 papers (2023–2023)Peisheng Hu · Xiamen University1 papers (2013–2013)Lily Guo · Duke University1 papers (2022–2022)Jessica Ortega · University of California, Los Angeles1 papers (2023–2023)James X. Wu · UCLA Medical Center1 papers (2023–2023) · 1 papers (2014–2014)Keegan Barry-Holson · Beth Israel Deaconess Medical Center1 papers (2013–2013)